- January, 08 2019
- December, 18 2018
GlaxoSmithKline’s latest deal to buy US cancer company Tesaro looks a bit like a strategic U-turn. In 2014, Sir Andrew Witty, then CEO, did a swap-deal with Novartis: it sold off the company’s established oncology business because it was un-competitive, a
Timing is of the essence for Novo Nordisk. The Danish company may use its priority review voucher to accelerate oral GLP-1 agonist candidate, semaglutide, past the regulators – though a decision is not confirmed. Buying a few more weeks – or months – to e
When Vectura’s nebulised form of budesonide, VR475, failed its Phase III asthma trial in late November 2018, the UK company blamed the drug, not the device. A conventional nebulizer also failed to significantly impact exacerbations, versus placebo.
It’s November, and if the men around you are sporting especially robust moustaches, don’t worry. It means they are paying attention to their health. During Movember--a mashup of “moustache” and “November”--men grow out their moustaches to raise awareness